Field Study Compares OSA With CSA for Measuring Efanesoctocog Alfa

Here is an open-access article contrasting the validity of OSA versus CSA for measuring efanesoctocog alfa (Altuviiio®) spiked into normal plasma: Pipe S, Sadeghi-Khomami A, Konkle BA, et al. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia. […]

Comments (0)

Factor Assays

Feb 13 2026

george

What is Red Light Therapy?

Check with your medical library for this in-depth review of red light Rx efficacy: Fan BE, Pasalic L, Hew YY, Lippi G, Favaloro EJ. Red light therapy in thrombosis and hemostasis. Semin Thromb Hemost. 2026;52:266–72. doi: 10.1055/a-2717-5157. PMID: 41062078. Abstract Red light therapy is emerging as a potential non-pharmacological modulator of thrombosis and hemostasis. Photobiomodulation […]

Antiplatelet Therapy

Enhanced Coagulation Potential FVIII

See this open-access article that describes a synthetic enhanced coagulation potential FVIII. This preparation reflects the enhanced activity FIX Padua. Kashiwakura Y, Nakajima Y, Horinaka K, et al. Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy. Blood. 2026;147:402–15. doi: 10.1182/blood.2025028481. PMID: 41198051. Abstract Click here for the visual […]

Bleeding Disorders

Review: VWD Type 2A

From Emmanuel Favaloro, PhD, Editor-in-Chief, Seminars in Thrombosis and Hemostasis: 2026 marks the 100th anniversary of the initial publication of a bleeding disorder, “pseudo-hemophilia’ that was later to become known as von Willebrand disease. Seminars in Thrombosis and Hemostasis will publish several papers on VWD in 2026. This is the first one in the queue–on […]

Bleeding Disorders

Low-dose Emicizumab Efficacy

Obtain this clinical research article on low-dose emicizumab therapy from your medical library: Datta G, Verma SP, Sinha S, et al. Bridging the Gap: Efficacy of low-dose emicizumab in haemophilia A with or without inhibitors. Haemophilia. 2026. doi: 10.1111/hae.70211. PMID: 41549560. ABSTRACT Introduction Emicizumab has proven to be a turning point in the management of […]

Bleeding Disorders

VWD In Women: Non-bleeding Health Issues

Click to read this open-access article that addresses the reproductive, medical, skeletal, psychosocial, and economic impact of VWD in women. Swan D, Sholzberg M, Bannow BS, Thachil J. Von Willebrand disease: more than just a bleeding disorder. Res Pract Thromb Haemost. 2025;10:103276. doi: 10.1016/j.rpth.2025.103276. PMID: 41536292; PMCID: PMC12796595. Abstract Von Willebrand disease (VWD) is the […]

Bleeding Disorders

Retrospective Comparison of rVWF versus pdVWF During Hospitalization

Here is an open-access article describing the efficacy of vonicog alfa versus plasma-derived VWF: Horvais V, Ternisien C, Denis-Le-Sève J, et al. Vonicog alfa versus plasma-derived von Willebrand factor during hospitalization: results of an observational retrospective multicenter study. Semin Thromb Hemost. 2026. doi: 10.1055/a-2779-9176. PMID: 41529718. Abstract Available products for the treatment of von Willebrand […]

Bleeding Disorders

Case: Thrombocytopenia

In a January 14, 2026 Diagnostic Equity post, an inquirer asked, “I was diagnosed with thrombocytopenia in 2024. I typically just go with the flow of what my doc and the nurse say. What are the lab tests that can help explain why my platelets are low, and how often should my platelets be monitored? […]

Bleeding Disorders

Review: The Effect of Exercise on Bleeding Disorders

This year is the 100th anniversary of the first VWD description, prompting several VWD updates, including Giuffrida AC, Gandini G, Focosi D, Franchini M. Impact of exercise/sport on well-being in von Willebrand disease and other congenital bleeding disorders: an update. Semin Thromb Hemost. 2026. doi: 10.1055/a-2778-9762. PMID: 41512904 available from your medical library. Abstract Worldwide, […]

Bleeding Disorders

Review: Desmopressin Therapy in Bleeding Disorders

Here is a 2025 open-access review that describes DDAVP Rx in hemophilia and VWD: Reardon B, Pasalic L, Favaloro EJ. A review of desmopressin use in bleeding disorders: an unsung hero? Biomolecules. 2025;15:967. doi: 10.3390/biom15070967. PMID: 40723839; PMCID: PMC12292229. Abstract As a synthetic analogue of vasopressin, desmopressin or DDAVP has well-established hemostatic properties. We present […]

Comments (0)

Bleeding Disorders

Bleeding Disorders

Field Study Compares OSA With CSA for Measuring Efanesoctocog Alfa

What is Red Light Therapy?

Enhanced Coagulation Potential FVIII

Review: VWD Type 2A

Low-dose Emicizumab Efficacy

VWD In Women: Non-bleeding Health Issues

Retrospective Comparison of rVWF versus pdVWF During Hospitalization

Case: Thrombocytopenia

Review: The Effect of Exercise on Bleeding Disorders

Review: Desmopressin Therapy in Bleeding Disorders

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question